Aster DM Health.

Aster DM is undergoing a massive transformation, having completed the GCC demerger and now moving toward a merger with Blackstone-backed Quality Care India Limited (QCIL). The combined entity will be a healthcare powerhouse with over 10,300 beds and pro-forma FY25 revenue of ₹8,105 crores. Management expects significant synergies in procurement and supply chain optimization, targeting an additional 100 basis points in margin improvement from scale alone. The merger is currently awaiting final NCLT and stock exchange approvals, with a target completion date in Q4 FY26.

The Kerala cluster, Aster's largest, faced a challenging Q4 with revenue growth of only 5% and a 6% decline in IPD volumes. Management attributed this to a full month of Ramadan impacting local footfalls and Medical Value Travel (MVT) from Maldives and Oman. Additionally, a leadership transition at the flagship Medcity unit caused some operational friction. However, the cluster maintained a healthy 23.4% EBITDA margin for the full year, and management expects a return to 'mid-teens' growth as new leadership settles in and 200 new beds are operationalized.

The company has a clear roadmap to add 2,100+ beds in India over the next 3-4 years. In Bangalore, Aster aims to exceed 2,000 beds, positioning itself among the top three providers in the city. Key projects include a new 430-bed hospital on Sarjapur Road and expansions at Aster Whitefield and CMI. In Kerala, 818 beds will be added, including greenfield projects in Kasargod and Trivandrum. This expansion will be funded primarily through internal accruals and existing cash reserves, as the company currently operates in a net cash position of ₹739 crores.

A central theme of the call was the structural improvement in EBITDA margins, which rose from 16.8% to 19.5% in FY25. This was driven by a 440 bps reduction in material costs (excluding wholesale pharmacy) since FY20 and a 70 bps improvement in manpower efficiency. Management has set a bold target of 23-24% margins within 3-4 years. Key levers include doubling volumes to gain procurement leverage, consolidating fragmented overheads like insurance and AMCs, and commissioning 30-32 MW of captive solar power plants to reduce energy costs.

Aster's lab business achieved a significant turnaround, moving from a negative EBITDA of ₹9 crore in FY24 to a positive ₹10 crore in FY25. The strategy is to increase the share of non-Aster (B2C/external B2B) business from the current 28% to 36-38% to drive higher margins. In the pharmacy segment, the company strategically exited loss-making wholesale segments, which artificially suppressed Q4 revenue growth but is expected to restore segment profitability by Q1 FY26. The retail pharmacy network now stands at 203 branded stores.